HB 5943 Summary

• Amends the Health Care False Claim Act to modify definitions and clarify language, including replacing "which" with "that" in multiple sections for grammatical accuracy.

• Removes the specific limitation that drug manufacturer rebates and discounts previously only applied to drugs treating multiple sclerosis, expanding the provision to apply to any drug.

• Adds new conditions for drug manufacturer rebates and discounts: the rebate cannot apply to drugs with lower-cost generic or biosimilar alternatives available on lower cost-sharing tiers, and must be made available to all eligible individuals regardless of payment method.

• Defines "eligible individual" as anyone not prohibited by state or federal law from receiving rebates, discounts, product vouchers, or other out-of-pocket expense reductions including copayments or deductibles.

• Specifies "health care services" that manufacturers may fund, including cardiac monitoring, blood work, vaccinations, and other clinically indicated services referenced in FDA-approved prescribing information.